GLPwatch
Trial of EXenatide in Acute Ischaemic Stroke
NCT03287076 · Unknown status
Last updated 2026-05-28This clinical trial is testing whether the drug exenatide can improve recovery in people who have recently had an acute ischemic stroke.
Status Unknown status The sponsor has not confirmed the status recently.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, single-blind treatment study
Participants 350 people
Who can join Ages 18+ · all sexes
Timeline Started 2017-11 · est. completion 2021-12
Where 15 sites · Australia, Finland, New Zealand
What this study is testing ClinicalTrials.gov NCT03287076 ↗
Description as written by the study sponsor.
A multicentre, randomised controlled Trial of Exenatide versus standard care in Acute Ischemic Stroke
Treatments tested
- Exenatide Injection also known as Byetta Drug
5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
| Main thing measured | improved neurological outcome |
|---|---|
| Sponsor | Neuroscience Trials Australia |
| Conditions studied | Acute Ischemic Stroke |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03287076 ↗